Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies

2.1 Sacituzumab govitecan (Trodelvy, Gilead Sciences) has a marketing authorisation for 'the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior lines of systemic therapies, at least one of them given for unresectable locally advanced or metastatic disease'.

2.2 The dosage schedule is available in the summary of product characteristics for sacituzumab govitecan.

2.3 The list price of sacituzumab govitecan is £793.00 per 180 mg vial (excluding VAT; BNF online accessed May 2022).

2.4 The company has a commercial arrangement. This makes sacituzumab govitecan available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.